Another ongoing phase II trial (NCT04661150) is evaluating the efficacy and safety of atezolizumab and trastuzumab in combination with capecitabine and oxaliplatin (XELOX) for patients with HER2-positive resectable locally-advanced GC/GEJA. The gene discussed is ERBB2; the disease is gastric cancer.